Unesbulin
- Generic Name
- Unesbulin
- Brand Names
- -
- Drug Type
- Small Molecule
- Chemical Formula
- C19H13F5N6
- CAS Number
- 1610964-64-1
- Unique Ingredient Identifier
- Z4HZ70S62Q
- Associated Conditions
- -
- Associated Therapies
- -
A Study of Unesbulin in Participants With Advanced Leiomyosarcoma (LMS)
Phase 2
Active, not recruiting
- Conditions
- Interventions
- First Posted Date
- 2022-03-08
- Last Posted Date
- 2024-06-21
- Lead Sponsor
- PTC Therapeutics
- Target Recruit Count
- 360
- Registration Number
- NCT05269355
- Locations
- ๐บ๐ธ
University of California, Los Angeles (UCLA) - Jonsson Comprehensive Cancer Center, Los Angeles, California, United States
๐บ๐ธNorthwestern Memorial Hospital, Chicago, Illinois, United States
๐บ๐ธThe Ohio State University (OSU), Columbus, Ohio, United States
A Study of Unesbulin (PTC596) in Combination With Dacarbazine in Participants With Advanced Leiomyosarcoma (LMS)
- First Posted Date
- 2018-12-03
- Last Posted Date
- 2024-03-15
- Lead Sponsor
- PTC Therapeutics
- Target Recruit Count
- 41
- Registration Number
- NCT03761095
- Locations
- ๐บ๐ธ
John Hopkins, Baltimore, Maryland, United States
๐บ๐ธMayo Clinic Florida, Jacksonville, Florida, United States
๐บ๐ธWashington University Medical Campus, Saint Louis, Missouri, United States
Unesbulin in Women With Ovarian Cancer Receiving Neoadjuvant Chemotherapy
- First Posted Date
- 2017-07-02
- Last Posted Date
- 2024-04-23
- Lead Sponsor
- University of Oklahoma
- Target Recruit Count
- 27
- Registration Number
- NCT03206645
- Locations
- ๐บ๐ธ
University of Oklahoma Health Sciences Center, Oklahoma City, Oklahoma, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.
ยฉ Copyright 2024. All Rights Reserved by MedPath